BR112021001012A2 - compostos de sulfonilureia como inibidores da atividade de interleucina-1 - Google Patents

Info

Publication number

BR112021001012A2

BR112021001012A2 BR112021001012-2A BR112021001012A BR112021001012A2 BR 112021001012 A2 BR112021001012 A2 BR 112021001012A2 BR 112021001012 A BR112021001012 A BR 112021001012A BR 112021001012 A2 BR112021001012 A2 BR 112021001012A2

Authority

BR

Brazil

Prior art keywords

c6alkyl

pharmaceutically acceptable

dihydro

pyrazolo

oxazine

Prior art date

2018-07-20

Links

• Espacenet
• Global Dossier
• Discuss

• 230000000694 effects Effects 0.000 title abstract description 10
• 239000003112 inhibitor Substances 0.000 title abstract description 5
• YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 title abstract description 4
• 102000000589 Interleukin-1 Human genes 0.000 title abstract description 3
• 108010002352 Interleukin-1 Proteins 0.000 title abstract description 3
• 150000001875 compounds Chemical class 0.000 claims abstract description 347
• 238000000034 method Methods 0.000 claims abstract description 118
• 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims abstract description 29
• 230000005764 inhibitory process Effects 0.000 claims abstract description 21
• 102000003810 Interleukin-18 Human genes 0.000 claims abstract description 15
• 108090000171 Interleukin-18 Proteins 0.000 claims abstract description 15
• 230000004913 activation Effects 0.000 claims abstract description 15
• 230000002757 inflammatory effect Effects 0.000 claims abstract description 7
• 125000000623 heterocyclic group Chemical group 0.000 claims description 240
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 201
• 150000003839 salts Chemical class 0.000 claims description 187
• -1 C4-C8cycloalkenyl Chemical group 0.000 claims description 170
• 239000012453 solvate Substances 0.000 claims description 164
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 149
• 125000006413 ring segment Chemical group 0.000 claims description 142
• 208000035475 disorder Diseases 0.000 claims description 130
• 125000001424 substituent group Chemical group 0.000 claims description 120
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 107
• 239000000651 prodrug Substances 0.000 claims description 91
• 229940002612 prodrug Drugs 0.000 claims description 91
• 239000008194 pharmaceutical composition Substances 0.000 claims description 83
• 125000001072 heteroaryl group Chemical group 0.000 claims description 74
• 229910052736 halogen Inorganic materials 0.000 claims description 68
• 150000002367 halogens Chemical class 0.000 claims description 67
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 56
• 201000006417 multiple sclerosis Diseases 0.000 claims description 52
• 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 44
• 229910052805 deuterium Inorganic materials 0.000 claims description 39
• 229910052739 hydrogen Inorganic materials 0.000 claims description 39
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 38
• 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims description 33
• 206010028980 Neoplasm Diseases 0.000 claims description 30
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 28
• 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 28
• 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims description 28
• 229910052757 nitrogen Inorganic materials 0.000 claims description 26
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 24
• 239000003814 drug Substances 0.000 claims description 22
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 21
• 125000004043 oxo group Chemical group O=* 0.000 claims description 21
• 108010034143 Inflammasomes Proteins 0.000 claims description 20
• 125000004429 atom Chemical group 0.000 claims description 19
• 201000010099 disease Diseases 0.000 claims description 17
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 15
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 15
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 15
• 201000011510 cancer Diseases 0.000 claims description 14
• 230000007812 deficiency Effects 0.000 claims description 14
• 230000004054 inflammatory process Effects 0.000 claims description 14
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 13
• 206010061218 Inflammation Diseases 0.000 claims description 13
• 238000004519 manufacturing process Methods 0.000 claims description 12
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 11
• 208000011580 syndromic disease Diseases 0.000 claims description 10
• 201000001320 Atherosclerosis Diseases 0.000 claims description 9
• 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 claims description 9
• 201000005569 Gout Diseases 0.000 claims description 9
• 108091008099 NLRP3 inflammasome Proteins 0.000 claims description 9
• 208000019423 liver disease Diseases 0.000 claims description 9
• 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 8
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 8
• 201000002795 Muckle-Wells syndrome Diseases 0.000 claims description 8
• 208000008589 Obesity Diseases 0.000 claims description 8
• 208000006673 asthma Diseases 0.000 claims description 8
• 210000003169 central nervous system Anatomy 0.000 claims description 8
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 8
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
• 235000020824 obesity Nutrition 0.000 claims description 8
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
• 208000002874 Acne Vulgaris Diseases 0.000 claims description 7
• 208000023275 Autoimmune disease Diseases 0.000 claims description 7
• 201000003274 CINCA syndrome Diseases 0.000 claims description 7
• 108090001005 Interleukin-6 Proteins 0.000 claims description 7
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 7
• 206010000496 acne Diseases 0.000 claims description 7
• 229940079593 drug Drugs 0.000 claims description 7
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
• 230000036210 malignancy Effects 0.000 claims description 7
• 206010072221 mevalonate kinase deficiency Diseases 0.000 claims description 7
• 102100026210 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Human genes 0.000 claims description 6
• 208000024827 Alzheimer disease Diseases 0.000 claims description 6
• 208000035143 Bacterial infection Diseases 0.000 claims description 6
• 208000009766 Blau syndrome Diseases 0.000 claims description 6
• 208000011231 Crohn disease Diseases 0.000 claims description 6
• 101000691589 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Proteins 0.000 claims description 6
• 102000013691 Interleukin-17 Human genes 0.000 claims description 6
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 6
• 208000005777 Lupus Nephritis Diseases 0.000 claims description 6
• 208000018737 Parkinson disease Diseases 0.000 claims description 6
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
• 208000036142 Viral infection Diseases 0.000 claims description 6
• 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 claims description 6
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
• 230000001684 chronic effect Effects 0.000 claims description 6
• 206010009887 colitis Diseases 0.000 claims description 6
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
• 208000002557 hidradenitis Diseases 0.000 claims description 6
• 201000007162 hidradenitis suppurativa Diseases 0.000 claims description 6
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 6
• 208000017169 kidney disease Diseases 0.000 claims description 6
• 206010025135 lupus erythematosus Diseases 0.000 claims description 6
• 208000002780 macular degeneration Diseases 0.000 claims description 6
• 150000003431 steroids Chemical class 0.000 claims description 6
• 230000009385 viral infection Effects 0.000 claims description 6
• 208000011594 Autoinflammatory disease Diseases 0.000 claims description 5
• 208000019693 Lung disease Diseases 0.000 claims description 5
• 210000000748 cardiovascular system Anatomy 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 210000005227 renal system Anatomy 0.000 claims description 5
• 230000004044 response Effects 0.000 claims description 5
• 230000009885 systemic effect Effects 0.000 claims description 5
• 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 4
• 208000007887 Alphavirus Infections Diseases 0.000 claims description 4
• 208000009137 Behcet syndrome Diseases 0.000 claims description 4
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
• 108700040132 Mevalonate kinases Proteins 0.000 claims description 4
• 206010046851 Uveitis Diseases 0.000 claims description 4
• 208000015114 central nervous system disease Diseases 0.000 claims description 4
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
• 208000010706 fatty liver disease Diseases 0.000 claims description 4
• 230000008938 immune dysregulation Effects 0.000 claims description 4
• 208000032839 leukemia Diseases 0.000 claims description 4
• 208000030159 metabolic disease Diseases 0.000 claims description 4
• 102000002678 mevalonate kinase Human genes 0.000 claims description 4
• 208000010125 myocardial infarction Diseases 0.000 claims description 4
• 201000008482 osteoarthritis Diseases 0.000 claims description 4
• 230000000737 periodic effect Effects 0.000 claims description 4
• 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 4
• 208000023504 respiratory system disease Diseases 0.000 claims description 4
• 208000017520 skin disease Diseases 0.000 claims description 4
• 208000012414 A20 haploinsufficiency Diseases 0.000 claims description 3
• 206010069754 Acquired gene mutation Diseases 0.000 claims description 3
• 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims description 3
• 206010053555 Arthritis bacterial Diseases 0.000 claims description 3
• 208000033116 Asbestos intoxication Diseases 0.000 claims description 3
• 206010063094 Cerebral malaria Diseases 0.000 claims description 3
• 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims description 3
• 208000015943 Coeliac disease Diseases 0.000 claims description 3
• 206010061788 Corneal infection Diseases 0.000 claims description 3
• 206010012310 Dengue fever Diseases 0.000 claims description 3
• 206010012559 Developmental delay Diseases 0.000 claims description 3
• 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
• 241001475178 Dira Species 0.000 claims description 3
• 208000021866 Dressler syndrome Diseases 0.000 claims description 3
• 206010017533 Fungal infection Diseases 0.000 claims description 3
• 208000006968 Helminthiasis Diseases 0.000 claims description 3
• 208000023105 Huntington disease Diseases 0.000 claims description 3
• 206010020772 Hypertension Diseases 0.000 claims description 3
• 206010061598 Immunodeficiency Diseases 0.000 claims description 3
• 208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
• 208000003456 Juvenile Arthritis Diseases 0.000 claims description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
• 208000009777 Majeed syndrome Diseases 0.000 claims description 3
• 206010027253 Meningitis pneumococcal Diseases 0.000 claims description 3
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
• 206010027476 Metastases Diseases 0.000 claims description 3
• 208000026072 Motor neurone disease Diseases 0.000 claims description 3
• 208000031888 Mycoses Diseases 0.000 claims description 3
• 206010031149 Osteitis Diseases 0.000 claims description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
• 206010065159 Polychondritis Diseases 0.000 claims description 3
• 201000004681 Psoriasis Diseases 0.000 claims description 3
• 206010037660 Pyrexia Diseases 0.000 claims description 3
• 206010063837 Reperfusion injury Diseases 0.000 claims description 3
• 201000010848 Schnitzler Syndrome Diseases 0.000 claims description 3
• 201000010001 Silicosis Diseases 0.000 claims description 3
• 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
• 206010040914 Skin reaction Diseases 0.000 claims description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
• 206010042496 Sunburn Diseases 0.000 claims description 3
• 208000010265 Sweet syndrome Diseases 0.000 claims description 3
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 3
• 208000002223 abdominal aortic aneurysm Diseases 0.000 claims description 3
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
• 208000007474 aortic aneurysm Diseases 0.000 claims description 3
• 206010003441 asbestosis Diseases 0.000 claims description 3
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
• 208000025255 bacterial arthritis Diseases 0.000 claims description 3
• 208000018339 bone inflammation disease Diseases 0.000 claims description 3
• 208000029028 brain injury Diseases 0.000 claims description 3
• 208000002849 chondrocalcinosis Diseases 0.000 claims description 3
• 208000020832 chronic kidney disease Diseases 0.000 claims description 3
• 208000024858 congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome Diseases 0.000 claims description 3
• 208000010247 contact dermatitis Diseases 0.000 claims description 3
• 208000031513 cyst Diseases 0.000 claims description 3
• 208000025729 dengue disease Diseases 0.000 claims description 3
• 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
• 201000010934 exostosis Diseases 0.000 claims description 3
• 208000030533 eye disease Diseases 0.000 claims description 3
• 210000004602 germ cell Anatomy 0.000 claims description 3
• 201000010930 hyperostosis Diseases 0.000 claims description 3
• 206010020718 hyperplasia Diseases 0.000 claims description 3
• 230000007813 immunodeficiency Effects 0.000 claims description 3
• 208000027866 inflammatory disease Diseases 0.000 claims description 3
• 206010022000 influenza Diseases 0.000 claims description 3
• 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 3
• 201000005202 lung cancer Diseases 0.000 claims description 3
• 208000020816 lung neoplasm Diseases 0.000 claims description 3
• 208000005264 motor neuron disease Diseases 0.000 claims description 3
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
• 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims description 3
• 208000008494 pericarditis Diseases 0.000 claims description 3
• 208000004593 pneumococcal meningitis Diseases 0.000 claims description 3
• 208000005987 polymyositis Diseases 0.000 claims description 3
• 230000000306 recurrent effect Effects 0.000 claims description 3
• 208000031162 sideroblastic anemia Diseases 0.000 claims description 3
• 201000005956 sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay Diseases 0.000 claims description 3
• 230000035483 skin reaction Effects 0.000 claims description 3
• 231100000430 skin reaction Toxicity 0.000 claims description 3
• 230000037439 somatic mutation Effects 0.000 claims description 3
• LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 3
• 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 claims description 3
• 230000035882 stress Effects 0.000 claims description 3
• 201000004595 synovitis Diseases 0.000 claims description 3
• 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 3
• 230000029663 wound healing Effects 0.000 claims description 3
• 208000004293 Chikungunya Fever Diseases 0.000 claims description 2
• 206010067256 Chikungunya virus infection Diseases 0.000 claims description 2
• 206010011732 Cyst Diseases 0.000 claims description 2
• 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
• 206010013774 Dry eye Diseases 0.000 claims description 2
• 206010066919 Epidemic polyarthritis Diseases 0.000 claims description 2
• 206010054261 Flavivirus infection Diseases 0.000 claims description 2
• 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
• 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 2
• 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims description 2
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 2
• 208000006011 Stroke Diseases 0.000 claims description 2
• 210000000068 Th17 cell Anatomy 0.000 claims description 2
• 208000001455 Zika Virus Infection Diseases 0.000 claims description 2
• 208000035332 Zika virus disease Diseases 0.000 claims description 2
• 208000020329 Zika virus infectious disease Diseases 0.000 claims description 2
• 206010012601 diabetes mellitus Diseases 0.000 claims description 2
• 230000008482 dysregulation Effects 0.000 claims description 2
• 208000030172 endocrine system disease Diseases 0.000 claims description 2
• 208000024908 graft versus host disease Diseases 0.000 claims description 2
• 125000005843 halogen group Chemical group 0.000 claims description 2
• 230000001900 immune effect Effects 0.000 claims description 2
• 208000026278 immune system disease Diseases 0.000 claims description 2
• 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims description 2
• 230000000968 intestinal effect Effects 0.000 claims description 2
• 230000000414 obstructive effect Effects 0.000 claims description 2
• 208000025487 periodic fever syndrome Diseases 0.000 claims description 2
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
• 208000031886 HIV Infections Diseases 0.000 claims 1
• 208000037357 HIV infectious disease Diseases 0.000 claims 1
• 206010019708 Hepatic steatosis Diseases 0.000 claims 1
• 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
• 102000004127 Cytokines Human genes 0.000 abstract description 5
• 108090000695 Cytokines Proteins 0.000 abstract description 5
• 230000008569 process Effects 0.000 abstract description 5
• 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 2
• 239000000203 mixture Substances 0.000 description 109
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 98
• 150000004677 hydrates Chemical class 0.000 description 76
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 75
• 239000000243 solution Substances 0.000 description 75
• 238000006243 chemical reaction Methods 0.000 description 73
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 70
• 238000003786 synthesis reaction Methods 0.000 description 66
• 230000015572 biosynthetic process Effects 0.000 description 65
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 64
• 238000002360 preparation method Methods 0.000 description 64
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 62
• 238000005481 NMR spectroscopy Methods 0.000 description 58
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 56
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 54
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 50
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 49
• MBGGXNNSIXSZBK-UHFFFAOYSA-N 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide Chemical compound NS(=O)(=O)C1=C2OCCCN2N=C1 MBGGXNNSIXSZBK-UHFFFAOYSA-N 0.000 description 47
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 42
• 229940124530 sulfonamide Drugs 0.000 description 42
• 239000007787 solid Substances 0.000 description 41
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 37
• LGOKKVLTOBWIQY-HNNXBMFYSA-N 1-[[(6S)-6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]-3-[6-methoxy-2,4-di(propan-2-yl)pyridin-3-yl]urea Chemical compound C(C1=C(NC(=O)NS(=O)(=O)C2=C3N(N=C2)C[C@@H](CO3)N2CC(OC)C2)C(C(C)C)=CC(OC)=N1)(C)C LGOKKVLTOBWIQY-HNNXBMFYSA-N 0.000 description 34
• 239000011541 reaction mixture Substances 0.000 description 33
• 230000002829 reductive effect Effects 0.000 description 31
• 229910021529 ammonia Inorganic materials 0.000 description 30
• 235000019439 ethyl acetate Nutrition 0.000 description 30
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
• CQPNIUCPFWNHID-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(2,2-dimethyl-3,4-dihydro-1H-naphthalen-1-yl)urea Chemical compound N12C(OCCC2)=C(S(=O)(=O)NC(=O)NC2C3=C(C=CC=C3)CCC2(C)C)C=N1 CQPNIUCPFWNHID-UHFFFAOYSA-N 0.000 description 25
• 125000003118 aryl group Chemical group 0.000 description 25
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 23
• 239000002904 solvent Substances 0.000 description 23
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
• 125000000753 cycloalkyl group Chemical group 0.000 description 20
• 238000004007 reversed phase HPLC Methods 0.000 description 20
• 125000004432 carbon atom Chemical group C* 0.000 description 19
• 125000000392 cycloalkenyl group Chemical group 0.000 description 18
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 17
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
• 239000000706 filtrate Substances 0.000 description 17
• 229910000104 sodium hydride Inorganic materials 0.000 description 16
• 238000003756 stirring Methods 0.000 description 16
• 238000001816 cooling Methods 0.000 description 15
• 239000002480 mineral oil Substances 0.000 description 15
• 235000010446 mineral oil Nutrition 0.000 description 15
• JAKVTKZGRNHXOQ-ZETCQYMHSA-N (6S)-6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide Chemical group COC1CN(C1)[C@H]1CN2C(OC1)=C(C=N2)S(=O)(=O)N JAKVTKZGRNHXOQ-ZETCQYMHSA-N 0.000 description 14
• HQOSHAQSVKYXAT-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(4,6-dimethylpyrimidin-2-yl)urea Chemical compound N12C(OCCC2)=C(S(=O)(=O)NC(=O)NC2=NC(=CC(=N2)C)C)C=N1 HQOSHAQSVKYXAT-UHFFFAOYSA-N 0.000 description 14
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 14
• 239000011734 sodium Substances 0.000 description 14
• UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 14
• LFUOACDTQBTACL-UHFFFAOYSA-N 6-methoxy-2,4-di(propan-2-yl)pyridin-3-amine Chemical compound C(C)(C)C1=NC(=CC(=C1N)C(C)C)OC LFUOACDTQBTACL-UHFFFAOYSA-N 0.000 description 13
• 108090000426 Caspase-1 Proteins 0.000 description 13
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
• 239000000908 ammonium hydroxide Substances 0.000 description 13
• 150000003863 ammonium salts Chemical class 0.000 description 13
• 239000012299 nitrogen atmosphere Substances 0.000 description 13
• 239000003921 oil Substances 0.000 description 13
• 235000019198 oils Nutrition 0.000 description 13
• 238000000746 purification Methods 0.000 description 13
• 239000000741 silica gel Substances 0.000 description 13
• 229910002027 silica gel Inorganic materials 0.000 description 13
• 229910052938 sodium sulfate Inorganic materials 0.000 description 13
• 235000011152 sodium sulphate Nutrition 0.000 description 13
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
• BXNUTDVMNFQGLN-UHFFFAOYSA-N 2,2-dimethyl-3,4-dihydro-1h-naphthalen-1-amine Chemical compound C1=CC=C2C(N)C(C)(C)CCC2=C1 BXNUTDVMNFQGLN-UHFFFAOYSA-N 0.000 description 12
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 12
• 229910052799 carbon Inorganic materials 0.000 description 12
• JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 12
• 229940011051 isopropyl acetate Drugs 0.000 description 12
• GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 12
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
• 102100035904 Caspase-1 Human genes 0.000 description 11
• 239000012267 brine Substances 0.000 description 11
• 239000010410 layer Substances 0.000 description 11
• 239000012044 organic layer Substances 0.000 description 11
• 239000000843 powder Substances 0.000 description 11
• 238000010898 silica gel chromatography Methods 0.000 description 11
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
• AFFQLMRPKKQLMT-YFKPBYRVSA-N (6S)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide Chemical compound CO[C@H]1CN2C(OC1)=C(C=N2)S(=O)(=O)N AFFQLMRPKKQLMT-YFKPBYRVSA-N 0.000 description 10
• JRYJZQGKZUQYAL-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-spiro[1,3-dihydroindene-2,4'-oxane]-1-ylurea Chemical compound C1=C2C(NC(=O)NS(=O)(=O)C=3C=NN4C=3OCCC4)C3(CCOCC3)CC2=CC=C1 JRYJZQGKZUQYAL-UHFFFAOYSA-N 0.000 description 10
• UVERRVWKZYVLRM-UHFFFAOYSA-N 6,6-dimethyl-5,7-dihydropyrazolo[5,1-b][1,3]oxazine-3-sulfonamide Chemical compound CC1(C)COC2=C(C=NN2C1)S(N)(=O)=O UVERRVWKZYVLRM-UHFFFAOYSA-N 0.000 description 10
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
• 239000012298 atmosphere Substances 0.000 description 10
• 125000004122 cyclic group Chemical group 0.000 description 10
• 239000006196 drop Substances 0.000 description 10
• 238000001914 filtration Methods 0.000 description 10
• 229910052760 oxygen Inorganic materials 0.000 description 10
• 239000003208 petroleum Substances 0.000 description 10
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
• 229920006395 saturated elastomer Polymers 0.000 description 10
• 239000012312 sodium hydride Substances 0.000 description 10
• 150000003456 sulfonamides Chemical class 0.000 description 10
• 239000003981 vehicle Substances 0.000 description 10
• HHJKBBNRCFZNCM-UHFFFAOYSA-N 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound O=S(=O)(NC(=O)NN1CC2C(CCC2)C1)C=1C=NN2C=1OCCC2 HHJKBBNRCFZNCM-UHFFFAOYSA-N 0.000 description 9
• VVQNFZIWSMDQFX-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[1-methyl-3,5-di(propan-2-yl)pyrazol-4-yl]urea Chemical compound N12C(OCCC2)=C(S(=O)(=O)NC(=O)NC=2C(C(C)C)=NN(C=2C(C)C)C)C=N1 VVQNFZIWSMDQFX-UHFFFAOYSA-N 0.000 description 9
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 9
• 239000002253 acid Substances 0.000 description 9
• 239000000543 intermediate Substances 0.000 description 9
• 239000000546 pharmaceutical excipient Substances 0.000 description 9
• 229910052708 sodium Inorganic materials 0.000 description 9
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 8
• CKJAOTZAHZVFOK-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(4,6-dimethoxypyrimidin-2-yl)urea Chemical compound COC1=NC(=NC(=C1)OC)NC(=O)NS(=O)(=O)C1=C2N(N=C1)CCCO2 CKJAOTZAHZVFOK-UHFFFAOYSA-N 0.000 description 8
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
• AFFQLMRPKKQLMT-UHFFFAOYSA-N 6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide Chemical compound COC1CN2C(OC1)=C(C=N2)S(=O)(=O)N AFFQLMRPKKQLMT-UHFFFAOYSA-N 0.000 description 8
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 8
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
• 239000000443 aerosol Substances 0.000 description 8
• 125000000217 alkyl group Chemical group 0.000 description 8
• 235000012538 ammonium bicarbonate Nutrition 0.000 description 8
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
• 229910052717 sulfur Inorganic materials 0.000 description 8
• 239000000725 suspension Substances 0.000 description 8
• ZXXSBBCSHUXEKD-ZDUSSCGKSA-N 1-[1-ethyl-3,5-di(propan-2-yl)pyrazol-4-yl]-3-[[(6S)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]urea Chemical compound C(C)N1N=C(C(=C1C(C)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)NC)C(C)C ZXXSBBCSHUXEKD-ZDUSSCGKSA-N 0.000 description 7
• 241000588653 Neisseria Species 0.000 description 7
• 210000004027 cell Anatomy 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 239000002552 dosage form Substances 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 208000024891 symptom Diseases 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 description 6
• APFFLONCCHTEQZ-UHFFFAOYSA-N 1-(4,6-dichloropyrimidin-2-yl)-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound C1CN2C(=C(C=N2)S(=O)(=O)NC(=O)NC3=NC(=CC(=N3)Cl)Cl)OC1 APFFLONCCHTEQZ-UHFFFAOYSA-N 0.000 description 6
• LJRWAQMHXFXTNO-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[3,5-di(propan-2-yl)-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]urea Chemical compound C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2)C(C)C)CC(F)(F)F LJRWAQMHXFXTNO-UHFFFAOYSA-N 0.000 description 6
• HCDNXBNQQRFFAD-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[3,5-di(propan-2-yl)-1-(trifluoromethyl)pyrazol-4-yl]urea Chemical compound C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2)C(C)C)C(F)(F)F HCDNXBNQQRFFAD-UHFFFAOYSA-N 0.000 description 6
• KPZHPQBXHODHEF-UHFFFAOYSA-N 4-nitro-3,5-di(propan-2-yl)-1h-pyrazole Chemical compound CC(C)C1=NNC(C(C)C)=C1[N+]([O-])=O KPZHPQBXHODHEF-UHFFFAOYSA-N 0.000 description 6
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• 239000007832 Na2SO4 Substances 0.000 description 6
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
• 125000003342 alkenyl group Chemical group 0.000 description 6
• PQNFLJBBNBOBRQ-UHFFFAOYSA-N benzocyclopentane Natural products C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 6
• 229910052794 bromium Inorganic materials 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 238000000576 coating method Methods 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 6
• 125000005842 heteroatom Chemical group 0.000 description 6
• 239000001257 hydrogen Substances 0.000 description 6
• 229910052740 iodine Inorganic materials 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 239000006187 pill Substances 0.000 description 6
• 229910000027 potassium carbonate Inorganic materials 0.000 description 6
• 239000007909 solid dosage form Substances 0.000 description 6
• 239000011593 sulfur Substances 0.000 description 6
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
• 239000011701 zinc Chemical class 0.000 description 6
• 229910052725 zinc Inorganic materials 0.000 description 6
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
• MVPSVZXQKUNYQJ-UHFFFAOYSA-N 1-[1-(2,2-difluoroethyl)-3,5-di(propan-2-yl)pyrazol-4-yl]-3-[(6,6-dimethyl-5,7-dihydropyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl]urea Chemical compound FC(CN1N=C(C(=C1C(C)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCC(C2)(C)C)C(C)C)F MVPSVZXQKUNYQJ-UHFFFAOYSA-N 0.000 description 5
• JXYUXZLCZLJGNU-LBPRGKRZSA-N 1-[2,4-di(propan-2-yl)-6-(trifluoromethyl)pyridin-3-yl]-3-[[(6S)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]urea Chemical compound O1C[C@H](CN2N=CC(=C12)S(=O)(=O)NC(=O)NC1=C(C(C)C)N=C(C=C1C(C)C)C(F)(F)F)OC JXYUXZLCZLJGNU-LBPRGKRZSA-N 0.000 description 5
• HXDWDZMHKVZEQG-NSHDSACASA-N 1-[[(6S)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]-3-(2-propan-2-yl-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl)urea Chemical compound C(C)(C)N1N=C2C(=C1NC(=O)NS(=O)(=O)C=1C=NN3C=1OC[C@H](C3)OC)CCC2 HXDWDZMHKVZEQG-NSHDSACASA-N 0.000 description 5
• XEFFILVRHIVAKO-UHFFFAOYSA-N 1-[[6-(aminomethyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]-3-propan-2-ylurea Chemical compound C(C1COC=2N(C1)N=CC=2S(=O)(=O)NC(=O)NC(C)C)N XEFFILVRHIVAKO-UHFFFAOYSA-N 0.000 description 5
• JTIIMKLOAHUGNQ-UHFFFAOYSA-N 1-ethyl-4-isocyanato-3,5-di(propan-2-yl)pyrazole Chemical compound CC(C1=NN(C(=C1N=C=O)C(C)C)CC)C JTIIMKLOAHUGNQ-UHFFFAOYSA-N 0.000 description 5
• IDQNBVFPZMCDDN-UHFFFAOYSA-N 2-Amino-4,6-dimethylpyrimidine Chemical compound CC1=CC(C)=NC(N)=N1 IDQNBVFPZMCDDN-UHFFFAOYSA-N 0.000 description 5
• YIJPYAZGWGWJKX-UHFFFAOYSA-N 6-chloro-3-nitro-2,4-di(propan-2-yl)pyridine Chemical compound CC(C)C1=CC(Cl)=NC(C(C)C)=C1[N+]([O-])=O YIJPYAZGWGWJKX-UHFFFAOYSA-N 0.000 description 5
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 5
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 5
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 5
• 238000010521 absorption reaction Methods 0.000 description 5
• 125000000304 alkynyl group Chemical group 0.000 description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
• 239000000460 chlorine Substances 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 229910017604 nitric acid Inorganic materials 0.000 description 5
• 239000001301 oxygen Substances 0.000 description 5
• 230000001717 pathogenic effect Effects 0.000 description 5
• 239000002244 precipitate Substances 0.000 description 5
• 238000010992 reflux Methods 0.000 description 5
• 239000000829 suppository Substances 0.000 description 5
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
• 239000001993 wax Substances 0.000 description 5
• 239000000080 wetting agent Substances 0.000 description 5
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
• KCAKPRFEPQPAEI-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(3-propan-2-yl-6,7-dihydro-5H-cyclopenta[c]pyridin-4-yl)urea Chemical compound N12C(OCCC2)=C(S(=O)(=O)NC(=O)NC2=C3C(=CN=C2C(C)C)CCC3)C=N1 KCAKPRFEPQPAEI-UHFFFAOYSA-N 0.000 description 4
• IDKDZXFYHLYEMK-UHFFFAOYSA-N 2-propan-2-yl-5,6-dihydro-4h-cyclopenta[c]pyrazole Chemical compound C1CCC2=NN(C(C)C)C=C21 IDKDZXFYHLYEMK-UHFFFAOYSA-N 0.000 description 4
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 4
• 241000725303 Human immunodeficiency virus Species 0.000 description 4
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
• 108091005686 NOD-like receptors Proteins 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
• 230000001594 aberrant effect Effects 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 150000001412 amines Chemical class 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 239000013078 crystal Substances 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 210000000750 endocrine system Anatomy 0.000 description 4
• 239000000945 filler Substances 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 230000014509 gene expression Effects 0.000 description 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
• 239000003701 inert diluent Substances 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 150000002540 isothiocyanates Chemical class 0.000 description 4
• 239000008101 lactose Substances 0.000 description 4
• 239000008263 liquid aerosol Substances 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 229910052763 palladium Inorganic materials 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 244000052769 pathogen Species 0.000 description 4
• UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 125000006239 protecting group Chemical group 0.000 description 4
• 210000002345 respiratory system Anatomy 0.000 description 4
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 159000000000 sodium salts Chemical class 0.000 description 4
• YMVUPRCAIPRDRJ-UHFFFAOYSA-N spiro[1,3-dihydroindene-2,4'-oxane]-1-amine Chemical compound NC1c2ccccc2CC11CCOCC1 YMVUPRCAIPRDRJ-UHFFFAOYSA-N 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• RBAJHCJYNCKLMN-UHFFFAOYSA-N 1-(3-bromo-6-methylpyridin-2-yl)-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound BrC=1C(=NC(=CC=1)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2 RBAJHCJYNCKLMN-UHFFFAOYSA-N 0.000 description 3
• PNCIEUIMJVPBKR-UHFFFAOYSA-N 1-(4-chloro-6-propan-2-ylpyrimidin-2-yl)-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound ClC1=NC(=NC(=C1)C(C)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2 PNCIEUIMJVPBKR-UHFFFAOYSA-N 0.000 description 3
• PQRLRDQJXFJNEG-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(2-phenylimidazo[1,2-a]pyridin-3-yl)urea Chemical compound C1(=CC=CC=C1)C=1N=C2N(C=CC=C2)C=1NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2 PQRLRDQJXFJNEG-UHFFFAOYSA-N 0.000 description 3
• VYFLTCWQJHOKDW-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(4-methyl-5,6,7,8-tetrahydroquinazolin-2-yl)urea Chemical compound CC1=C2CCCCC2=NC(=N1)NC(=O)NS(=O)(=O)C3=C4N(CCCO4)N=C3 VYFLTCWQJHOKDW-UHFFFAOYSA-N 0.000 description 3
• LLUPLQQJIGOHJR-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(5-methyl-2-propan-2-ylpyrazol-3-yl)urea Chemical compound N1(C(C)C)C(NC(=O)NS(=O)(=O)C2=C3N(N=C2)CCCO3)=CC(C)=N1 LLUPLQQJIGOHJR-UHFFFAOYSA-N 0.000 description 3
• CHAWPMXPZVTVMZ-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[1,3,5-tri(propan-2-yl)pyrazol-4-yl]urea Chemical compound C(C)(C)N1N=C(C(=C1C(C)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2)C(C)C CHAWPMXPZVTVMZ-UHFFFAOYSA-N 0.000 description 3
• NEXBHNLFJWQQBD-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[1-ethyl-3,5-di(propan-2-yl)pyrazol-4-yl]urea Chemical compound CCN1C(=C(C(=N1)C(C)C)NC(=O)NS(=O)(=O)C2=C3N(CCCO3)N=C2)C(C)C NEXBHNLFJWQQBD-UHFFFAOYSA-N 0.000 description 3
• QUGJNRBMMYBBNA-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[2,4-di(propan-2-yl)pyridin-3-yl]urea Chemical compound CC(C1=C(NC(=O)NS(=O)(=O)C2=C3N(N=C2)CCCO3)C(C(C)C)=NC=C1)C QUGJNRBMMYBBNA-UHFFFAOYSA-N 0.000 description 3
• WTLSLAFPBIFJKF-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[2-(2-methoxypyridin-4-yl)-4-propan-2-yl-6-(trifluoromethyl)pyridin-3-yl]urea Chemical compound C(C)(C)C1=C(C(=NC(=C1)C(F)(F)F)C1=CC(=NC=C1)OC)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2 WTLSLAFPBIFJKF-UHFFFAOYSA-N 0.000 description 3
• NZGYTJADMKGGNM-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[3,5-di(propan-2-yl)pyridin-4-yl]urea Chemical compound CC(C1=C(NC(=O)NS(=O)(=O)C2=C3N(N=C2)CCCO3)C(C(C)C)=CN=C1)C NZGYTJADMKGGNM-UHFFFAOYSA-N 0.000 description 3
• KWLLGDYASZIWPZ-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[6-(methylamino)-2,4-di(propan-2-yl)pyridin-3-yl]urea Chemical compound CC(C1=C(NC(=O)NS(=O)(=O)C2=C3N(N=C2)CCCO3)C(C(C)C)=NC(NC)=C1)C KWLLGDYASZIWPZ-UHFFFAOYSA-N 0.000 description 3
• OHRAHXIOHMCFKK-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[6-methoxy-2,4-di(propan-2-yl)pyridin-3-yl]urea Chemical compound C1(C(C)C)=C(NC(=O)NS(=O)(=O)C2=C3N(N=C2)CCCO3)C(C(C)C)=NC(OC)=C1 OHRAHXIOHMCFKK-UHFFFAOYSA-N 0.000 description 3
• GELFMHXRWJXKRM-UHFFFAOYSA-N 1-[3,5-bis(prop-1-en-2-yl)pyridin-4-yl]-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound C=C(C)C=1C=NC=C(C=1NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2)C(=C)C GELFMHXRWJXKRM-UHFFFAOYSA-N 0.000 description 3
• MATWRJDFNMRPNC-NSHDSACASA-N 1-[3,5-di(propan-2-yl)-1-(trifluoromethyl)pyrazol-4-yl]-3-[[(6S)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]urea Chemical compound C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)NC)C(C)C)C(F)(F)F MATWRJDFNMRPNC-NSHDSACASA-N 0.000 description 3
• YCDSARSBBUBJBM-NSHDSACASA-N 1-[3,5-di(propan-2-yl)-1-(trifluoromethyl)pyrazol-4-yl]-3-[[(6S)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]urea Chemical compound C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)OC)C(C)C)C(F)(F)F YCDSARSBBUBJBM-NSHDSACASA-N 0.000 description 3
• NMAFMMDEESBUQD-UHFFFAOYSA-N 1-[6-chloro-2,4-di(propan-2-yl)pyridin-3-yl]-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound ClC1=CC(=C(C(=N1)C(C)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2)C(C)C NMAFMMDEESBUQD-UHFFFAOYSA-N 0.000 description 3
• AFPJKEDQOVDSFG-UHFFFAOYSA-N 1-[6-cyclopropyl-2,4-di(propan-2-yl)pyridin-3-yl]-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound N12C(OCCC2)=C(S(=O)(=O)NC(=O)NC2=C(C(C)C)N=C(C=C2C(C)C)C2CC2)C=N1 AFPJKEDQOVDSFG-UHFFFAOYSA-N 0.000 description 3
• HCTCEPIWQJCRPQ-ZDUSSCGKSA-N 1-[6-methoxy-2,4-di(propan-2-yl)pyridin-3-yl]-3-[[(6S)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]urea Chemical compound C(C)(C)C1=NC(=CC(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)NC)C(C)C)OC HCTCEPIWQJCRPQ-ZDUSSCGKSA-N 0.000 description 3
• COTVPEFYLNVOAE-LBPRGKRZSA-N 1-[[(6S)-6-(dimethylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]-3-(2-propan-2-yl-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl)urea Chemical compound CN([C@H]1CN2C(OC1)=C(C=N2)S(=O)(=O)NC(NC1=C2C(=NN1C(C)C)CCC2)=O)C COTVPEFYLNVOAE-LBPRGKRZSA-N 0.000 description 3
• FKXZEBTTWSRQCQ-AWEZNQCLSA-N 1-[[(6S)-6-(dimethylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]-3-[6-methoxy-2,4-di(propan-2-yl)pyridin-3-yl]urea Chemical compound C(C)(C)C1=NC(=CC(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)N(C)C)C(C)C)OC FKXZEBTTWSRQCQ-AWEZNQCLSA-N 0.000 description 3
• WHCRXKQHOFDCAG-LBPRGKRZSA-N 1-[[(6S)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]-3-[1-methyl-3,5-di(propan-2-yl)pyrazol-4-yl]urea Chemical compound C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)OC)C(C)C)C WHCRXKQHOFDCAG-LBPRGKRZSA-N 0.000 description 3
• AUISWYMVLJYSLG-UHFFFAOYSA-N 1-methyl-3,5-di(propan-2-yl)pyrazol-4-amine Chemical compound C(C=1C(N)=C(C(C)C)N(N=1)C)(C)C AUISWYMVLJYSLG-UHFFFAOYSA-N 0.000 description 3
• AKWIUNBJAXHBRR-UHFFFAOYSA-N 1-methyl-4-nitro-3,5-di(propan-2-yl)pyrazole Chemical compound N1(C(=C(C(=N1)C(C)C)N(=O)=O)C(C)C)C AKWIUNBJAXHBRR-UHFFFAOYSA-N 0.000 description 3
• HOMVWUSAKOVOEI-UHFFFAOYSA-N 2,4-bis(prop-1-en-2-yl)-6-(trifluoromethoxy)pyridin-3-amine Chemical compound C=C(C)C1=NC(=CC(=C1N)C(=C)C)OC(F)(F)F HOMVWUSAKOVOEI-UHFFFAOYSA-N 0.000 description 3
• HWMQOXMFMJQEET-UHFFFAOYSA-N 2,4-di(propan-2-yl)-6-(trifluoromethoxy)pyridin-3-amine Chemical compound C(C)(C)C1=NC(=CC(=C1N)C(C)C)OC(F)(F)F HWMQOXMFMJQEET-UHFFFAOYSA-N 0.000 description 3
• NJEIQJJENGNCEZ-UHFFFAOYSA-N 2,4-di(propan-2-yl)-6-(trifluoromethyl)pyridin-3-amine Chemical compound C(C)(C)C1=NC(=CC(=C1N)C(C)C)C(F)(F)F NJEIQJJENGNCEZ-UHFFFAOYSA-N 0.000 description 3
• NXSFYZFWPXLBIO-UHFFFAOYSA-N 2,4-dibromo-6-(trifluoromethoxy)pyridin-3-amine Chemical compound Nc1c(Br)cc(OC(F)(F)F)nc1Br NXSFYZFWPXLBIO-UHFFFAOYSA-N 0.000 description 3
• YQONMUDGUYLNIE-UHFFFAOYSA-N 2-(2-methoxypyridin-4-yl)-4-propan-2-yl-6-(trifluoromethyl)pyridin-3-amine Chemical compound C(C)(C)C1=C(C(=NC(=C1)C(F)(F)F)C1=CC(=NC=C1)OC)N YQONMUDGUYLNIE-UHFFFAOYSA-N 0.000 description 3
• MQWMIVQDCPIWJP-UHFFFAOYSA-N 2-bromo-4-propan-2-yl-6-(trifluoromethyl)pyridin-3-amine Chemical compound BrC1=NC(=CC(=C1N)C(C)C)C(F)(F)F MQWMIVQDCPIWJP-UHFFFAOYSA-N 0.000 description 3
• RLNNWMRRKNVYEU-UHFFFAOYSA-N 2-oxo-4,6-di(propan-2-yl)-1H-pyridine-3-carbonitrile Chemical compound CC(C)c1cc(C(C)C)c(C#N)c(=O)[nH]1 RLNNWMRRKNVYEU-UHFFFAOYSA-N 0.000 description 3
• BHAFGZLBNXBIQJ-UHFFFAOYSA-N 2-propan-2-yl-6-(trifluoromethyl)pyridin-3-amine Chemical compound NC=1C(=NC(=CC=1)C(F)(F)F)C(C)C BHAFGZLBNXBIQJ-UHFFFAOYSA-N 0.000 description 3
• YJQQIOCVQGFUMW-UHFFFAOYSA-N 3-isocyanato-2-(2-methoxypyridin-4-yl)-4-propan-2-yl-6-(trifluoromethyl)pyridine Chemical compound N(=C=O)C=1C(=NC(=CC=1C(C)C)C(F)(F)F)C1=CC(=NC=C1)OC YJQQIOCVQGFUMW-UHFFFAOYSA-N 0.000 description 3
• BLACILKWUGSOFQ-UHFFFAOYSA-N 3-isocyanato-4-(2-methoxypyridin-4-yl)-2-propan-2-yl-6-(trifluoromethyl)pyridine Chemical compound N(=C=O)C=1C(=NC(=CC=1C1=CC(=NC=C1)OC)C(F)(F)F)C(C)C BLACILKWUGSOFQ-UHFFFAOYSA-N 0.000 description 3
• RHDWUHAEQAJCCJ-UHFFFAOYSA-N 3-nitro-2,4-di(propan-2-yl)-6-(trifluoromethyl)pyridine Chemical compound C(C)(C)C1=NC(=CC(=C1[N+](=O)[O-])C(C)C)C(F)(F)F RHDWUHAEQAJCCJ-UHFFFAOYSA-N 0.000 description 3
• BLZCPSURHZWDRY-UHFFFAOYSA-N 3-propan-2-yl-6,7-dihydro-5H-cyclopenta[c]pyridin-4-amine Chemical compound C(C)(C)C1=C(C2=C(C=N1)CCC2)N BLZCPSURHZWDRY-UHFFFAOYSA-N 0.000 description 3
• JCPZDAQYGJQXIZ-UHFFFAOYSA-N 3-propan-2-yl-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carbonitrile Chemical compound C(C)(C)C1=C(C2=C(C=N1)CCC2)C#N JCPZDAQYGJQXIZ-UHFFFAOYSA-N 0.000 description 3
• SJXRTYTZSSEDMI-UHFFFAOYSA-N 3-propan-2-yl-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carboxylic acid Chemical compound C(C)(C)C1=C(C2=C(C=N1)CCC2)C(=O)O SJXRTYTZSSEDMI-UHFFFAOYSA-N 0.000 description 3
• PTPBTXHZGKZLHR-UHFFFAOYSA-N 4-(2-methoxypyridin-4-yl)-2-propan-2-yl-6-(trifluoromethyl)pyridin-3-amine Chemical compound C(C)(C)C1=NC(=CC(=C1N)C1=CC(=NC=C1)OC)C(F)(F)F PTPBTXHZGKZLHR-UHFFFAOYSA-N 0.000 description 3
• DNXBJMXCXGPWMZ-UHFFFAOYSA-N 4-bromo-2-propan-2-yl-6-(trifluoromethyl)pyridin-3-amine Chemical compound BrC1=C(C(=NC(=C1)C(F)(F)F)C(C)C)N DNXBJMXCXGPWMZ-UHFFFAOYSA-N 0.000 description 3
• FTAPPHQQAXHUGX-UHFFFAOYSA-N 4-isocyanato-3,5-di(propan-2-yl)-1-(trifluoromethyl)pyrazole Chemical compound N(=C=O)C=1C(=NN(C=1C(C)C)C(F)(F)F)C(C)C FTAPPHQQAXHUGX-UHFFFAOYSA-N 0.000 description 3
• QZNVMHRFWKAVDB-UHFFFAOYSA-N 4-nitro-3,5-di(propan-2-yl)-1-(2,2,2-trifluoroethyl)pyrazole Chemical compound C(C)(C)C1=NN(C(=C1[N+](=O)[O-])C(C)C)CC(F)(F)F QZNVMHRFWKAVDB-UHFFFAOYSA-N 0.000 description 3
• NVYZQTGVQSYBHY-UHFFFAOYSA-N 4-propan-2-yl-6-(trifluoromethyl)pyridin-3-amine Chemical compound CC(C)C1=CC(C(F)(F)F)=NC=C1N NVYZQTGVQSYBHY-UHFFFAOYSA-N 0.000 description 3
• IKCQKRZYBYPAQB-UHFFFAOYSA-N 5-nitro-2-oxo-4,6-di(propan-2-yl)-1H-pyridine-3-carbonitrile Chemical compound OC1=C(C#N)C(=C(C(=N1)C(C)C)[N+](=O)[O-])C(C)C IKCQKRZYBYPAQB-UHFFFAOYSA-N 0.000 description 3
• OXQQACPEXOPYRH-UHFFFAOYSA-N 5-nitro-4,6-di(propan-2-yl)-1H-pyridin-2-one Chemical compound C(C)(C)C1=CC(=NC(=C1[N+](=O)[O-])C(C)C)O OXQQACPEXOPYRH-UHFFFAOYSA-N 0.000 description 3
• YNCBSDCMLFVMBE-UHFFFAOYSA-N 5-nitro-4-prop-1-en-2-yl-2-(trifluoromethyl)pyridine Chemical compound [N+](=O)([O-])C=1C(=CC(=NC=1)C(F)(F)F)C(=C)C YNCBSDCMLFVMBE-UHFFFAOYSA-N 0.000 description 3
• CYGQHJPWKGFBBS-UHFFFAOYSA-N 6-cyclopropyl-2,4-di(propan-2-yl)pyridin-3-amine Chemical compound C1(CC1)C1=CC(=C(C(=N1)C(C)C)N)C(C)C CYGQHJPWKGFBBS-UHFFFAOYSA-N 0.000 description 3
• YYHYQTYHTMQZIX-UHFFFAOYSA-N 6-iodo-3-nitro-2,4-di(propan-2-yl)pyridine Chemical compound IC1=CC(=C(C(=N1)C(C)C)[N+](=O)[O-])C(C)C YYHYQTYHTMQZIX-UHFFFAOYSA-N 0.000 description 3
• JITRGLKYKHLIHK-UHFFFAOYSA-N 6-methoxy-3-nitro-2,4-di(propan-2-yl)pyridine Chemical compound C(C)(C)C1=NC(=CC(=C1[N+](=O)[O-])C(C)C)OC JITRGLKYKHLIHK-UHFFFAOYSA-N 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• PIYHKTNFUBWMNS-UHFFFAOYSA-N CC(CCN1N=C2C)OC1=C2S(N)(=O)=O Chemical compound CC(CCN1N=C2C)OC1=C2S(N)(=O)=O PIYHKTNFUBWMNS-UHFFFAOYSA-N 0.000 description 3
• CVMOTRJJUQTRKI-UHFFFAOYSA-N CNC1=NN2C(OCCC2)=C1S(=O)(=O)N Chemical compound CNC1=NN2C(OCCC2)=C1S(=O)(=O)N CVMOTRJJUQTRKI-UHFFFAOYSA-N 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• 102000012064 NLR Proteins Human genes 0.000 description 3
• 239000004698 Polyethylene Substances 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 210000003123 bronchiole Anatomy 0.000 description 3
• 239000006172 buffering agent Substances 0.000 description 3
• 229910000024 caesium carbonate Inorganic materials 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 239000003995 emulsifying agent Substances 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 235000019441 ethanol Nutrition 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 239000012065 filter cake Substances 0.000 description 3
• 229910052731 fluorine Inorganic materials 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• INQOMBQAUSQDDS-BJUDXGSMSA-N iodomethane Chemical group I[11CH3] INQOMBQAUSQDDS-BJUDXGSMSA-N 0.000 description 3
• 239000008297 liquid dosage form Substances 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 239000006199 nebulizer Substances 0.000 description 3
• 230000027544 negative regulation of NLRP3 inflammasome complex assembly Effects 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 235000015320 potassium carbonate Nutrition 0.000 description 3
• 235000011181 potassium carbonates Nutrition 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 229960004063 propylene glycol Drugs 0.000 description 3
• 235000018102 proteins Nutrition 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 230000007115 recruitment Effects 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 239000007921 spray Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 239000000375 suspending agent Substances 0.000 description 3
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 229910052722 tritium Inorganic materials 0.000 description 3
• DHQMUJSACXTPEA-UHFFFAOYSA-N (2-methoxypyridin-4-yl)boronic acid Chemical compound COC1=CC(B(O)O)=CC=N1 DHQMUJSACXTPEA-UHFFFAOYSA-N 0.000 description 2
• USPHVATWBUGBPS-QMMMGPOBSA-N (6S)-6-(3-methoxyazetidin-1-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine Chemical compound COC1CN(C1)[C@H]1CN2C(OC1)=CC=N2 USPHVATWBUGBPS-QMMMGPOBSA-N 0.000 description 2
• PGIZAEGOKCIZIF-LURJTMIESA-N (6S)-6-(dimethylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide Chemical compound CN([C@H]1CN2C(OC1)=C(C=N2)S(=O)(=O)N)C PGIZAEGOKCIZIF-LURJTMIESA-N 0.000 description 2
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• KTKCZYDOTVEGSZ-UHFFFAOYSA-N 1-(2,5-ditert-butylpyrazol-3-yl)-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound O1CCCN2C1=C(S(=O)(=O)NC(=O)NC=1N(C(C)(C)C)N=C(C=1)C(C)(C)C)C=N2 KTKCZYDOTVEGSZ-UHFFFAOYSA-N 0.000 description 2
• QZGOPYWFQWHQKE-UHFFFAOYSA-N 1-(3,4-dihydro-2H-chromen-4-yl)-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound C1=C2C(NC(=O)NS(=O)(=O)C3=C4N(N=C3)CCCO4)CCOC2=CC=C1 QZGOPYWFQWHQKE-UHFFFAOYSA-N 0.000 description 2
• FBBHOWVZATWICO-UHFFFAOYSA-N 1-(4,6-ditert-butylpyrimidin-2-yl)-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound CC(C1=NC(=NC(C(C)(C)C)=C1)NC(=O)NS(=O)(=O)C1=C2N(N=C1)CCCO2)(C)C FBBHOWVZATWICO-UHFFFAOYSA-N 0.000 description 2
• SETAANVTPKACEG-UHFFFAOYSA-N 1-(4-cyclopropyl-6-methylpyrimidin-2-yl)-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound N1=C(C=C(N=C1NC(=O)NS(=O)(=O)C1=C2N(N=C1)CCCO2)C)C1CC1 SETAANVTPKACEG-UHFFFAOYSA-N 0.000 description 2
• WSBVDLYLBXQLCC-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(1-phenylcycloheptyl)urea Chemical compound C1CC(NC(=O)NS(=O)(=O)C2=C3N(N=C2)CCCO3)(C2=CC=CC=C2)CCCC1 WSBVDLYLBXQLCC-UHFFFAOYSA-N 0.000 description 2
• LRMTYGDLIWXJQK-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(1-phenylcyclopropyl)urea Chemical compound C1(=CC=CC=C1)C1(NC(=O)NS(=O)(=O)C2=C3N(N=C2)CCCO3)CC1 LRMTYGDLIWXJQK-UHFFFAOYSA-N 0.000 description 2
• RPXIBLIVNFESBI-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(2,6-dimethylpiperidin-1-yl)urea Chemical compound N1(C(CCCC1C)C)NC(=O)NS(=O)(=O)C1=C2N(N=C1)CCCO2 RPXIBLIVNFESBI-UHFFFAOYSA-N 0.000 description 2
• DFIGBJRIVUAYCV-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(2-methyl-2,3-dihydro-1H-inden-1-yl)urea Chemical compound CC1CC2=CC=CC=C2C1NC(=O)NS(=O)(=O)C3=C4N(CCCO4)N=C3 DFIGBJRIVUAYCV-UHFFFAOYSA-N 0.000 description 2
• NRTSPUIZSRDQFN-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(2-propan-2-yl-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl)urea Chemical compound C(C)(C)N1N=C2C(=C1NC(=O)NS(=O)(=O)C=1C=NN3C=1OCCC3)CCC2 NRTSPUIZSRDQFN-UHFFFAOYSA-N 0.000 description 2
• DPWHPPZZFHIJKY-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(3-phenyl-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl)urea Chemical compound C1(=CC=CC=C1)C1=CC2=C(C(=N1)NC(=O)NS(=O)(=O)C=1C=NN3C=1OCCC3)CCC2 DPWHPPZZFHIJKY-UHFFFAOYSA-N 0.000 description 2
• BHOZKLMTUBYWTN-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(4-methoxy-6-methylpyrimidin-2-yl)urea Chemical compound COC1=NC(=NC(=C1)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2 BHOZKLMTUBYWTN-UHFFFAOYSA-N 0.000 description 2
• MBJTXIJKWARKNK-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(5-methyl-3-phenyl-1,2-oxazol-4-yl)urea Chemical compound C1=CC=CC=C1C=1C(NC(=O)NS(=O)(=O)C2=C3N(N=C2)CCCO3)=C(C)ON=1 MBJTXIJKWARKNK-UHFFFAOYSA-N 0.000 description 2
• ZZFASVAUNIGTCI-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(5-oxo-1,2,3,6,7,8-hexahydropyrrolo[1,2-a]indol-4-yl)urea Chemical compound O=C1C=2C(NC(=O)NS(=O)(=O)C3=C4N(N=C3)CCCO4)=C3CCCN3C=2CCC1 ZZFASVAUNIGTCI-UHFFFAOYSA-N 0.000 description 2
• LWAVQYZGRZCTLY-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(9H-fluoren-9-yl)urea Chemical compound N12C(OCCC2)=C(S(=O)(=O)NC(=O)NC2C3=CC=CC=C3C3=C2C=CC=C3)C=N1 LWAVQYZGRZCTLY-UHFFFAOYSA-N 0.000 description 2
• JLNRDTAVGOPGHT-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[2,4-di(propan-2-yl)-6-(trifluoromethoxy)pyridin-3-yl]urea Chemical compound C(C)(C)C1=NC(=CC(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2)C(C)C)OC(F)(F)F JLNRDTAVGOPGHT-UHFFFAOYSA-N 0.000 description 2
• CVOMVEJGYOXHGE-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[4-(2-methoxypyridin-4-yl)-2-propan-2-yl-6-(trifluoromethyl)pyridin-3-yl]urea Chemical compound C(C)(C)C1=NC(=CC(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2)C1=CC(=NC=C1)OC)C(F)(F)F CVOMVEJGYOXHGE-UHFFFAOYSA-N 0.000 description 2
• WALQETFDKQIBNN-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[4-phenyl-6-(trifluoromethyl)pyrimidin-2-yl]urea Chemical compound C(C1=NC(=NC(C2=CC=CC=C2)=C1)NC(=O)NS(=O)(=O)C1=C2N(N=C1)CCCO2)(F)(F)F WALQETFDKQIBNN-UHFFFAOYSA-N 0.000 description 2
• YKJIISIOQUEXNR-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[6-methyl-2,4-di(propan-2-yl)pyridin-3-yl]urea Chemical compound C1N2C(OCC1)=C(C=N2)S(=O)(=O)NC(=O)NC1=C(C(C)C)C=C(C)N=C1C(C)C YKJIISIOQUEXNR-UHFFFAOYSA-N 0.000 description 2
• YKTOYYSTGAPSRG-UHFFFAOYSA-N 1-(azepan-1-yl)-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound O=S(=O)(NC(=O)NN1CCCCCC1)C1=C2N(N=C1)CCCO2 YKTOYYSTGAPSRG-UHFFFAOYSA-N 0.000 description 2
• DTSLSGXNSCACOV-UHFFFAOYSA-N 1-[(6,6-dimethyl-5,7-dihydropyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl]-3-[1-ethyl-3,5-di(propan-2-yl)pyrazol-4-yl]urea Chemical compound C(C)N1N=C(C(=C1C(C)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCC(C2)(C)C)C(C)C DTSLSGXNSCACOV-UHFFFAOYSA-N 0.000 description 2
• FXMAZACHFKNSFW-UHFFFAOYSA-N 1-[(6,6-dimethyl-5,7-dihydropyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl]-3-[1-methyl-3,5-di(propan-2-yl)pyrazol-4-yl]urea Chemical compound C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OCC(C2)(C)C)C(C)C)C FXMAZACHFKNSFW-UHFFFAOYSA-N 0.000 description 2
• ZHMYKNNHNVWQIY-UHFFFAOYSA-N 1-[(6,6-dimethyl-5,7-dihydropyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl]-3-[3,5-di(propan-2-yl)-1-(trifluoromethyl)pyrazol-4-yl]urea Chemical compound C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OCC(C2)(C)C)C(C)C)C(F)(F)F ZHMYKNNHNVWQIY-UHFFFAOYSA-N 0.000 description 2
• FJQVJRGZPFOEMH-UHFFFAOYSA-N 1-[(6,6-dimethyl-5,7-dihydropyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl]-3-[6-methoxy-2,4-di(propan-2-yl)pyridin-3-yl]urea Chemical compound C(C)(C)C1=NC(=CC(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OCC(C2)(C)C)C(C)C)OC FJQVJRGZPFOEMH-UHFFFAOYSA-N 0.000 description 2
• IULOWLMUZYHUHI-UHFFFAOYSA-N 1-[1-(2,2-difluoroethyl)-3,5-di(propan-2-yl)pyrazol-4-yl]-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound C1(=C(N(N=C1C(C)C)CC(F)F)C(C)C)NC(=O)NS(=O)(=O)C1=C2N(N=C1)CCCO2 IULOWLMUZYHUHI-UHFFFAOYSA-N 0.000 description 2
• VQCRBASUHLTYCC-LBPRGKRZSA-N 1-[1-(2,2-difluoroethyl)-3,5-di(propan-2-yl)pyrazol-4-yl]-3-[[(6S)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]urea Chemical compound CC(C)C1=C(C(=NN1CC(F)F)C(C)C)NC(=O)NS(=O)(=O)C2=C3N(C[C@@H](CO3)NC)N=C2 VQCRBASUHLTYCC-LBPRGKRZSA-N 0.000 description 2
• FWLOUKCZAHVLGB-UHFFFAOYSA-N 1-[1-(cyclopropylmethyl)-3,5-di(propan-2-yl)pyrazol-4-yl]-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound C1(CC1)CN1N=C(C(=C1C(C)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2)C(C)C FWLOUKCZAHVLGB-UHFFFAOYSA-N 0.000 description 2
• LMJLDCAGGOWAOO-ZDUSSCGKSA-N 1-[1-ethyl-3,5-di(propan-2-yl)pyrazol-4-yl]-3-[[(6S)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]urea Chemical compound CCN1C(=C(C(=N1)C(C)C)NC(=O)NS(=O)(=O)C2=C3N(C[C@@H](CO3)OC)N=C2)C(C)C LMJLDCAGGOWAOO-ZDUSSCGKSA-N 0.000 description 2
• MXXMIQAIQQZBJX-UHFFFAOYSA-N 1-[6-cyano-2,4-di(propan-2-yl)pyridin-3-yl]-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound C1N2C(OCC1)=C(C=N2)S(=O)(=O)NC(=O)NC1=C(C(C)C)N=C(C=C1C(C)C)C#N MXXMIQAIQQZBJX-UHFFFAOYSA-N 0.000 description 2
• QRVQQXFPVIJIBB-UHFFFAOYSA-N 1-[6-cyclopropyloxy-2,4-di(propan-2-yl)pyridin-3-yl]-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound C1(CC1)OC1=CC(=C(C(=N1)C(C)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2)C(C)C QRVQQXFPVIJIBB-UHFFFAOYSA-N 0.000 description 2
• UDEUZMOOTVFOOB-ZDUSSCGKSA-N 1-[[(6S)-6-(dimethylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonyl]-3-[2,4-di(propan-2-yl)-6-(trifluoromethyl)pyridin-3-yl]urea Chemical compound C(C)(C)C1=NC(=CC(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)N(C)C)C(C)C)C(F)(F)F UDEUZMOOTVFOOB-ZDUSSCGKSA-N 0.000 description 2
• IHZHMCJLTKIZIH-UHFFFAOYSA-N 1-ethyl-3,5-di(propan-2-yl)pyrazol-4-amine Chemical compound C(C)N1N=C(C(=C1C(C)C)N)C(C)C IHZHMCJLTKIZIH-UHFFFAOYSA-N 0.000 description 2
• 238000005160 1H NMR spectroscopy Methods 0.000 description 2
• PFRCMEYXYHDZFK-YFKPBYRVSA-N 2,2,2-trifluoro-N-methyl-N-[(6S)-3-sulfamoyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl]acetamide Chemical compound CN([C@H]1CN2C(=C(C=N2)S(=O)(=O)N)OC1)C(=O)C(F)(F)F PFRCMEYXYHDZFK-YFKPBYRVSA-N 0.000 description 2
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
• CQCGLMBJVRDWGL-UHFFFAOYSA-N 2,5-ditert-butylpyrazol-3-amine Chemical compound CC(C)(C)C=1C=C(N)N(C(C)(C)C)N=1 CQCGLMBJVRDWGL-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• IRLHCPSNKZJFIY-UHFFFAOYSA-N 2-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide Chemical compound COC1=NN2C(OCCC2)=C1S(=O)(=O)N IRLHCPSNKZJFIY-UHFFFAOYSA-N 0.000 description 2
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
• QJPWWLKPLICOLS-UHFFFAOYSA-N 3,3-dimethyl-2,4-dihydro-1h-naphthalene Chemical compound C1=CC=C2CC(C)(C)CCC2=C1 QJPWWLKPLICOLS-UHFFFAOYSA-N 0.000 description 2
• WPYNXKFLSQEEFE-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-amine;hydrochloride Chemical group Cl.C1CCC2CN(N)CC21 WPYNXKFLSQEEFE-UHFFFAOYSA-N 0.000 description 2
• XPVMUYQYHNYROK-UHFFFAOYSA-N 3-isocyanato-2,4-di(propan-2-yl)-6-(trifluoromethoxy)pyridine Chemical compound N(=C=O)C=1C(=NC(=CC=1C(C)C)OC(F)(F)F)C(C)C XPVMUYQYHNYROK-UHFFFAOYSA-N 0.000 description 2
• RJWYUTANIMSNOA-UHFFFAOYSA-N 3-nitro-2-prop-1-en-2-yl-6-(trifluoromethyl)pyridine Chemical compound [N+](=O)([O-])C=1C(=NC(=CC=1)C(F)(F)F)C(=C)C RJWYUTANIMSNOA-UHFFFAOYSA-N 0.000 description 2
• XBNGIRCOLKNWIJ-UHFFFAOYSA-N 3-prop-1-en-2-yl-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carbonitrile Chemical compound C=C(C)C1=C(C2=C(C=N1)CCC2)C#N XBNGIRCOLKNWIJ-UHFFFAOYSA-N 0.000 description 2
• SVSUYEJKNSMKKW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-1-en-2-yl-1,3,2-dioxaborolane Chemical compound CC(=C)B1OC(C)(C)C(C)(C)O1 SVSUYEJKNSMKKW-UHFFFAOYSA-N 0.000 description 2
• LVFRCHIUUKWBLR-CDYZYAPPSA-N 4,6-dimethoxypyrimidin-2-amine Chemical group COC1=CC(OC)=NC([15NH2])=N1 LVFRCHIUUKWBLR-CDYZYAPPSA-N 0.000 description 2
• WDGJQAKMBHPTAB-UHFFFAOYSA-N 4,6-ditert-butylpyrimidin-2-amine Chemical group CC(C)(C)C1=CC(C(C)(C)C)=NC(N)=N1 WDGJQAKMBHPTAB-UHFFFAOYSA-N 0.000 description 2
• QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
• CFTWPFWVTSDTQO-UHFFFAOYSA-N 4-isocyanato-1-methyl-3,5-di(propan-2-yl)pyrazole Chemical compound N(=C=O)C=1C(=NN(C=1C(C)C)C)C(C)C CFTWPFWVTSDTQO-UHFFFAOYSA-N 0.000 description 2
• PNRINVUWRWZYLW-UHFFFAOYSA-N 4-isocyanato-3,3-dimethyl-2,4-dihydro-1H-naphthalene Chemical compound CC1(CCC2=CC=CC=C2C1N=C=O)C PNRINVUWRWZYLW-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
• 241000710929 Alphavirus Species 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 208000022715 Autoinflammatory syndrome Diseases 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• AIAVTJHCVCNAHL-UHFFFAOYSA-N C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OCC(C2)(C)C)C(C)C)CC(F)(F)F Chemical compound C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OCC(C2)(C)C)C(C)C)CC(F)(F)F AIAVTJHCVCNAHL-UHFFFAOYSA-N 0.000 description 2
• LLDUTVLPOZDLJG-LBPRGKRZSA-N C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)NC)C(C)C)CC(F)(F)F Chemical compound C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)NC)C(C)C)CC(F)(F)F LLDUTVLPOZDLJG-LBPRGKRZSA-N 0.000 description 2
• LUJRVIVDYWYOHF-LBPRGKRZSA-N C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)OC)C(C)C)CC(F)(F)F Chemical compound C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)OC)C(C)C)CC(F)(F)F LUJRVIVDYWYOHF-LBPRGKRZSA-N 0.000 description 2
• RYDBQLVXUFAYGF-UHFFFAOYSA-N CC(C)C1=CC(=NC(=C1NC(=O)NS(=O)(=O)C2=C3N(CCCO3)N=C2)C(C)C)C(F)(F)F Chemical compound CC(C)C1=CC(=NC(=C1NC(=O)NS(=O)(=O)C2=C3N(CCCO3)N=C2)C(C)C)C(F)(F)F RYDBQLVXUFAYGF-UHFFFAOYSA-N 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• 241000725619 Dengue virus Species 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• SBQCZHIQQOPPLY-LBPRGKRZSA-N FC(CN1N=C(C(=C1C(C)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)OC)C(C)C)F Chemical compound FC(CN1N=C(C(=C1C(C)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)OC)C(C)C)F SBQCZHIQQOPPLY-LBPRGKRZSA-N 0.000 description 2
• 241000710831 Flavivirus Species 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 2
• 229910004373 HOAc Inorganic materials 0.000 description 2
• 101000833614 Homo sapiens Interferon-inducible protein AIM2 Proteins 0.000 description 2
• 102100024064 Interferon-inducible protein AIM2 Human genes 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• 241000186781 Listeria Species 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• RFJNZFJQBZALCP-UHFFFAOYSA-N N-[[3-[[6-methoxy-2,4-di(propan-2-yl)pyridin-3-yl]carbamoylsulfamoyl]-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl]methyl]acetamide Chemical compound CC(C1=C(NC(=O)NS(=O)(=O)C2=C3N(N=C2)CC(CNC(=O)C)CO3)C(C(C)C)=NC(OC)=C1)C RFJNZFJQBZALCP-UHFFFAOYSA-N 0.000 description 2
• QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
• UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
• 229910002651 NO3 Inorganic materials 0.000 description 2
• 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
• 239000005642 Oleic acid Substances 0.000 description 2
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 101150034459 Parpbp gene Proteins 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 241000194017 Streptococcus Species 0.000 description 2
• 241000193998 Streptococcus pneumoniae Species 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 241000907316 Zika virus Species 0.000 description 2
• XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
• RCHGIZYRJZCTQC-RXMQYKEDSA-N [(6R)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl] trifluoromethanesulfonate Chemical compound N1=CC=C2OC[C@@H](CN21)OS(=O)(=O)C(F)(F)F RCHGIZYRJZCTQC-RXMQYKEDSA-N 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 229920002988 biodegradable polymer Polymers 0.000 description 2
• 239000004621 biodegradable polymer Substances 0.000 description 2
• GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
• 235000019437 butane-1,3-diol Nutrition 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 235000013877 carbamide Nutrition 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 238000004296 chiral HPLC Methods 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 239000012230 colorless oil Substances 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• 239000002702 enteric coating Substances 0.000 description 2
• 238000009505 enteric coating Methods 0.000 description 2
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000012467 final product Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 2
• KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
• 229940093915 gynecological organic acid Drugs 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
• IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 2
• 150000002430 hydrocarbons Chemical group 0.000 description 2
• 239000005457 ice water Substances 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 239000004530 micro-emulsion Substances 0.000 description 2
• 230000002025 microglial effect Effects 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
• 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
• 125000006574 non-aromatic ring group Chemical group 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 108010089193 pattern recognition receptors Proteins 0.000 description 2
• 102000007863 pattern recognition receptors Human genes 0.000 description 2
• 239000002304 perfume Substances 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 238000012877 positron emission topography Methods 0.000 description 2
• 239000011591 potassium Chemical class 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 238000002953 preparative HPLC Methods 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 2
• 230000006010 pyroptosis Effects 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
• 239000008159 sesame oil Substances 0.000 description 2
• 235000011803 sesame oil Nutrition 0.000 description 2
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• 235000012239 silicon dioxide Nutrition 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
• 235000011149 sulphuric acid Nutrition 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• XVHQRNYPEVCHCO-UHFFFAOYSA-N tert-butyl N-(3-propan-2-yl-6,7-dihydro-5H-cyclopenta[c]pyridin-4-yl)carbamate Chemical compound C(C)(C)C1=C(C2=C(C=N1)CCC2)NC(OC(C)(C)C)=O XVHQRNYPEVCHCO-UHFFFAOYSA-N 0.000 description 2
• YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
• WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 241000712461 unidentified influenza virus Species 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• PAORVUMOXXAMPL-SECBINFHSA-N (2s)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 1
• QBIRNWYMLTVIOP-RXMQYKEDSA-N (6R)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-ol Chemical compound N1=CC=C2OC[C@@H](CN21)O QBIRNWYMLTVIOP-RXMQYKEDSA-N 0.000 description 1
• VZJMHWNTTWPURI-YFKPBYRVSA-N (6S)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide Chemical compound CN[C@H]1CN2C(OC1)=C(C=N2)S(=O)(=O)N VZJMHWNTTWPURI-YFKPBYRVSA-N 0.000 description 1
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• RKOUFQLNMRAACI-UHFFFAOYSA-N 1,1,1-trifluoro-2-iodoethane Chemical compound FC(F)(F)CI RKOUFQLNMRAACI-UHFFFAOYSA-N 0.000 description 1
• VMFCTZUYOILUMY-UHFFFAOYSA-N 1,1-difluoro-2-iodoethane Chemical compound FC(F)CI VMFCTZUYOILUMY-UHFFFAOYSA-N 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• SORRPQQUGZHGSM-UHFFFAOYSA-N 1-(2,2-difluoroethyl)-3,5-di(propan-2-yl)pyrazol-4-amine Chemical compound FC(CN1N=C(C(=C1C(C)C)N)C(C)C)F SORRPQQUGZHGSM-UHFFFAOYSA-N 0.000 description 1
• LYMUPDHMGQWMHZ-UHFFFAOYSA-N 1-(2,2-difluoroethyl)-4-isocyanato-3,5-di(propan-2-yl)pyrazole Chemical compound CC(C)C1=C(C(=NN1CC(F)F)C(C)C)N=C=O LYMUPDHMGQWMHZ-UHFFFAOYSA-N 0.000 description 1
• COPNYAAOVJNEQM-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-[6-ethoxy-2,4-di(propan-2-yl)pyridin-3-yl]urea Chemical compound N12CCCOC1=C(C=N2)S(=O)(=O)NC(=O)NC1=C(C(C)C)N=C(C=C1C(C)C)OCC COPNYAAOVJNEQM-UHFFFAOYSA-N 0.000 description 1
• QKRBYYKHBWPRLD-UHFFFAOYSA-N 1-[(6,6-dimethyl-5,7-dihydropyrazolo[5,1-b][1,3]oxazin-3-yl)sulfonyl]-3-(2-propan-2-yl-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl)urea Chemical compound CC(C)N1C(=C2CCCC2=N1)NC(=O)NS(=O)(=O)C3=C4N(CC(CO4)(C)C)N=C3 QKRBYYKHBWPRLD-UHFFFAOYSA-N 0.000 description 1
• LMERULGJSBNXMF-UHFFFAOYSA-N 1-benzhydryl-3-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)urea Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2 LMERULGJSBNXMF-UHFFFAOYSA-N 0.000 description 1
• SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
• RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
• LTWBQSVETWWOFJ-UHFFFAOYSA-N 1-phenylcycloheptan-1-amine Chemical compound C=1C=CC=CC=1C1(N)CCCCCC1 LTWBQSVETWWOFJ-UHFFFAOYSA-N 0.000 description 1
• OYRBDGKUVUVWRI-UHFFFAOYSA-N 1-phenylcyclopropan-1-amine Chemical compound C=1C=CC=CC=1C1(N)CC1 OYRBDGKUVUVWRI-UHFFFAOYSA-N 0.000 description 1
• FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• CGSQRQAFFZYNRK-UHFFFAOYSA-N 2,3-dimethylbutane-2,3-diol prop-1-en-2-ylboronic acid Chemical class CC(=C)B(O)O.CC(C)(O)C(C)(C)O CGSQRQAFFZYNRK-UHFFFAOYSA-N 0.000 description 1
• CEGGECULKVTYMM-UHFFFAOYSA-N 2,6-dimethylheptane-3,5-dione Chemical compound CC(C)C(=O)CC(=O)C(C)C CEGGECULKVTYMM-UHFFFAOYSA-N 0.000 description 1
• UAHWWAIVYPJROV-UHFFFAOYSA-N 2,6-dimethylpiperidin-1-amine Chemical compound CC1CCCC(C)N1N UAHWWAIVYPJROV-UHFFFAOYSA-N 0.000 description 1
• LFEAEPFLXYINBS-UHFFFAOYSA-N 2-N,2-N-dimethyl-4,6-di(propan-2-yl)pyridine-2,5-diamine Chemical compound C(C)(C)C1=CC(=NC(=C1N)C(C)C)N(C)C LFEAEPFLXYINBS-UHFFFAOYSA-N 0.000 description 1
• MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
• QAZZMFLLNSJCLW-UHFFFAOYSA-N 2-chloro-6-(trifluoromethyl)pyridin-3-amine Chemical compound NC1=CC=C(C(F)(F)F)N=C1Cl QAZZMFLLNSJCLW-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
• GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 1
• PTOLXLSYGKBIJB-UHFFFAOYSA-N 2-methyl-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(N)C(C)CC2=C1 PTOLXLSYGKBIJB-UHFFFAOYSA-N 0.000 description 1
• 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
• KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
• RJGJCHYNEWULMZ-UHFFFAOYSA-N 2-phenylimidazo[1,2-a]pyridin-3-amine Chemical compound N1=C2C=CC=CN2C(N)=C1C1=CC=CC=C1 RJGJCHYNEWULMZ-UHFFFAOYSA-N 0.000 description 1
• LVZWIAPBWHFMOV-UHFFFAOYSA-N 2-propan-2-yl-5,6-dihydro-4h-cyclopenta[c]pyrazol-3-amine Chemical compound C1CCC2=C(N)N(C(C)C)N=C21 LVZWIAPBWHFMOV-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• UJKWNDSSVUXYTJ-UHFFFAOYSA-N 2H-cyclopenta[c]pyridine-4-carbonitrile Chemical compound C=1NC=C(C=2C1C=CC2)C#N UJKWNDSSVUXYTJ-UHFFFAOYSA-N 0.000 description 1
• BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
• FJYWNYLUZBMVKI-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-amine Chemical group C1CCC2CN(N)CC21 FJYWNYLUZBMVKI-UHFFFAOYSA-N 0.000 description 1
• LCOFMNJNNXWKOC-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-4-amine Chemical compound C1=CC=C2C(N)CCOC2=C1 LCOFMNJNNXWKOC-UHFFFAOYSA-N 0.000 description 1
• HGSYGKQRPJDICP-UHFFFAOYSA-N 3,5-bis(prop-1-en-2-yl)pyridin-4-amine Chemical compound C=C(C)C=1C=NC=C(C=1N)C(=C)C HGSYGKQRPJDICP-UHFFFAOYSA-N 0.000 description 1
• BYUPPAUVEZZTAD-UHFFFAOYSA-N 3,5-di(propan-2-yl)-1-(2,2,2-trifluoroethyl)pyrazol-4-amine Chemical compound C(C)(C)C1=NN(C(=C1N)C(C)C)CC(F)(F)F BYUPPAUVEZZTAD-UHFFFAOYSA-N 0.000 description 1
• BABPJVBMLBRFBF-UHFFFAOYSA-N 3,5-di(propan-2-yl)-1-(trifluoromethyl)pyrazol-4-amine Chemical compound C(C)(C)C1=NN(C(=C1N)C(C)C)C(F)(F)F BABPJVBMLBRFBF-UHFFFAOYSA-N 0.000 description 1
• PJSJVTZSFIRYIZ-UHFFFAOYSA-N 3,5-di(propan-2-yl)-1h-pyrazole Chemical compound CC(C)C=1C=C(C(C)C)NN=1 PJSJVTZSFIRYIZ-UHFFFAOYSA-N 0.000 description 1
• ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
• CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• JYWWGZAAXTYNRN-UHFFFAOYSA-N 3-bromo-6-methylpyridin-2-amine Chemical compound CC1=CC=C(Br)C(N)=N1 JYWWGZAAXTYNRN-UHFFFAOYSA-N 0.000 description 1
• UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
• ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
• FLEGGCQGXMOSQW-UHFFFAOYSA-N 3-chloro-6,7-dihydro-5h-cyclopenta[c]pyridine-4-carbonitrile Chemical compound ClC1=NC=C2CCCC2=C1C#N FLEGGCQGXMOSQW-UHFFFAOYSA-N 0.000 description 1
• NSCFXLDHUUIADR-UHFFFAOYSA-N 3-isocyanato-2-propan-2-yl-5,6-dihydro-4H-cyclopenta[c]pyrazole Chemical compound N(=C=O)C1=C2C(=NN1C(C)C)CCC2 NSCFXLDHUUIADR-UHFFFAOYSA-N 0.000 description 1
• KSXGQRBTBLQJEF-UHFFFAOYSA-N 3-methoxyazetidine;hydrochloride Chemical compound Cl.COC1CNC1 KSXGQRBTBLQJEF-UHFFFAOYSA-N 0.000 description 1
• 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
• NHGCVIIPNIZFJM-UHFFFAOYSA-N 3-methylpyridine-2,5-diamine Chemical compound CC1=CC(N)=CN=C1N NHGCVIIPNIZFJM-UHFFFAOYSA-N 0.000 description 1
• JPZOAVGMSDSWSW-UHFFFAOYSA-N 4,6-dichloropyrimidin-2-amine Chemical compound NC1=NC(Cl)=CC(Cl)=N1 JPZOAVGMSDSWSW-UHFFFAOYSA-N 0.000 description 1
• JPZOAVGMSDSWSW-SUEIGJEOSA-N 4,6-dichloropyrimidin-2-amine Chemical group NC1=N[13C](Cl)=C[13C](Cl)=N1 JPZOAVGMSDSWSW-SUEIGJEOSA-N 0.000 description 1
• LVFRCHIUUKWBLR-UHFFFAOYSA-N 4,6-dimethoxypyrimidin-2-amine Chemical compound COC1=CC(OC)=NC(N)=N1 LVFRCHIUUKWBLR-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
• VBVLYVRVIUJULO-UHFFFAOYSA-N 4-chloro-5-nitro-2-(trifluoromethyl)pyridine Chemical compound [O-][N+](=O)C1=CN=C(C(F)(F)F)C=C1Cl VBVLYVRVIUJULO-UHFFFAOYSA-N 0.000 description 1
• SPMMDFHRMVXLLO-UHFFFAOYSA-N 4-chloro-6-propan-2-ylpyrimidin-2-amine Chemical compound CC(C)C1=CC(Cl)=NC(N)=N1 SPMMDFHRMVXLLO-UHFFFAOYSA-N 0.000 description 1
• KPMMRZPKAYBHME-UHFFFAOYSA-N 4-cyclopropyl-6-methylpyrimidin-2-amine Chemical compound NC1=NC(C)=CC(C2CC2)=N1 KPMMRZPKAYBHME-UHFFFAOYSA-N 0.000 description 1
• XIFAFLLBBWXBAM-UHFFFAOYSA-N 4-isocyanato-3,5-di(propan-2-yl)-1-(2,2,2-trifluoroethyl)pyrazole Chemical compound N(=C=O)C=1C(=NN(C=1C(C)C)CC(F)(F)F)C(C)C XIFAFLLBBWXBAM-UHFFFAOYSA-N 0.000 description 1
• SNWZXTZIZWBIDQ-UHFFFAOYSA-N 4-methoxy-6-methylpyrimidin-2-amine Chemical compound COC1=CC(C)=NC(N)=N1 SNWZXTZIZWBIDQ-UHFFFAOYSA-N 0.000 description 1
• 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
• SNRKDMNNDAVJSI-UHFFFAOYSA-N 4-methyl-5,6,7,8-tetrahydroquinazolin-2-amine Chemical compound C1CCCC2=C1N=C(N)N=C2C SNRKDMNNDAVJSI-UHFFFAOYSA-N 0.000 description 1
• SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 1
• ZHXBPRJAAQLLMC-UHFFFAOYSA-N 4-phenyl-6-(trifluoromethyl)pyrimidin-2-amine Chemical compound FC(F)(F)C1=NC(N)=NC(C=2C=CC=CC=2)=C1 ZHXBPRJAAQLLMC-UHFFFAOYSA-N 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• VERUFXOALATMPS-UHFFFAOYSA-N 5,5-diamino-2-(2-phenylethenyl)cyclohex-3-ene-1,1-disulfonic acid Chemical compound C1=CC(N)(N)CC(S(O)(=O)=O)(S(O)(=O)=O)C1C=CC1=CC=CC=C1 VERUFXOALATMPS-UHFFFAOYSA-N 0.000 description 1
• CKOZVEHVVHCMGD-UHFFFAOYSA-N 5-[(4-fluorophenyl)methyl]-n,n-dimethyltetrazole-1-carboxamide Chemical compound CN(C)C(=O)N1N=NN=C1CC1=CC=C(F)C=C1 CKOZVEHVVHCMGD-UHFFFAOYSA-N 0.000 description 1
• QWMOVJWPTZATFS-UHFFFAOYSA-N 5-methyl-3-phenyl-1,2-oxazol-4-amine Chemical compound NC1=C(C)ON=C1C1=CC=CC=C1 QWMOVJWPTZATFS-UHFFFAOYSA-N 0.000 description 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
• IASRYLKZYZPWRV-UHFFFAOYSA-N 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine Chemical compound C1CCOC2=CC=NN21 IASRYLKZYZPWRV-UHFFFAOYSA-N 0.000 description 1
• HYBWXJYCVPLEPI-UHFFFAOYSA-N 6-(trifluoromethoxy)pyridin-3-amine Chemical compound NC1=CC=C(OC(F)(F)F)N=C1 HYBWXJYCVPLEPI-UHFFFAOYSA-N 0.000 description 1
• ABKSYZFBMOLMGG-UHFFFAOYSA-N 6-chloro-2,4-di(propan-2-yl)pyridin-3-amine Chemical compound CC(C)C1=CC(Cl)=NC(C(C)C)=C1N ABKSYZFBMOLMGG-UHFFFAOYSA-N 0.000 description 1
• FZVPHTSHJBTIEG-UHFFFAOYSA-N 6-cyclopropyloxy-3-nitro-2,4-di(propan-2-yl)pyridine Chemical compound C1(CC1)OC1=CC(=C(C(=N1)C(C)C)[N+](=O)[O-])C(C)C FZVPHTSHJBTIEG-UHFFFAOYSA-N 0.000 description 1
• OUGMRQJTULXVDC-UHFFFAOYSA-N 9h-fluoren-9-amine Chemical compound C1=CC=C2C(N)C3=CC=CC=C3C2=C1 OUGMRQJTULXVDC-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 208000026326 Adult-onset Still disease Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 241000223836 Babesia Species 0.000 description 1
• 241000193738 Bacillus anthracis Species 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• GZYWBEMUXOGSJH-LBPRGKRZSA-N C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)NC)C(C)C)C Chemical compound C(C)(C)C1=NN(C(=C1NC(=O)NS(=O)(=O)C=1C=NN2C=1OC[C@H](C2)NC)C(C)C)C GZYWBEMUXOGSJH-LBPRGKRZSA-N 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• IKPWWBMVECJVEN-UHFFFAOYSA-N C1(=CC=CC=C1)C1=CC2=C(C(=N1)N)CCC2 Chemical compound C1(=CC=CC=C1)C1=CC2=C(C(=N1)N)CCC2 IKPWWBMVECJVEN-UHFFFAOYSA-N 0.000 description 1
• CTMDYYXPSFXPJJ-UHFFFAOYSA-N C1CCN2C1=CC1C(CCCC21)=O Chemical compound C1CCN2C1=CC1C(CCCC21)=O CTMDYYXPSFXPJJ-UHFFFAOYSA-N 0.000 description 1
• HHJKBBNRCFZNCM-QWRGUYRKSA-N C1N(C[C@H]2[C@H]1CCC2)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2 Chemical compound C1N(C[C@H]2[C@H]1CCC2)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2 HHJKBBNRCFZNCM-QWRGUYRKSA-N 0.000 description 1
• KHTYKVVWVPFNAT-UHFFFAOYSA-N CC(C)(CCC1=CC=CC=C11)C1NC(N1N(CCCO2)C2=CC1)=O Chemical compound CC(C)(CCC1=CC=CC=C11)C1NC(N1N(CCCO2)C2=CC1)=O KHTYKVVWVPFNAT-UHFFFAOYSA-N 0.000 description 1
• CQPNIUCPFWNHID-MRXNPFEDSA-N CC1([C@@H](C2=CC=CC=C2CC1)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2)C Chemical compound CC1([C@@H](C2=CC=CC=C2CC1)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2)C CQPNIUCPFWNHID-MRXNPFEDSA-N 0.000 description 1
• GYBWJSQXNSLFIW-ZETCQYMHSA-N CN([C@H]1CN2C(OC1)=CC=N2)C Chemical compound CN([C@H]1CN2C(OC1)=CC=N2)C GYBWJSQXNSLFIW-ZETCQYMHSA-N 0.000 description 1
• LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
• 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 102000004091 Caspase-8 Human genes 0.000 description 1
• 108090000538 Caspase-8 Proteins 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000242722 Cestoda Species 0.000 description 1
• 201000009182 Chikungunya Diseases 0.000 description 1
• 241001502567 Chikungunya virus Species 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 241000193155 Clostridium botulinum Species 0.000 description 1
• 241000193449 Clostridium tetani Species 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical class [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 208000001490 Dengue Diseases 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 241000224431 Entamoeba Species 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• SBQCZHIQQOPPLY-UHFFFAOYSA-N FC(CN1N=C(C(=C1C(C)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCC(C2)OC)C(C)C)F Chemical compound FC(CN1N=C(C(=C1C(C)C)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCC(C2)OC)C(C)C)F SBQCZHIQQOPPLY-UHFFFAOYSA-N 0.000 description 1
• 208000004930 Fatty Liver Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 102100037388 Gasdermin-D Human genes 0.000 description 1
• 101710087939 Gasdermin-D Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 241000224466 Giardia Species 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 241000219146 Gossypium Species 0.000 description 1
• 108700010013 HMGB1 Proteins 0.000 description 1
• 101150021904 HMGB1 gene Proteins 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 241000590002 Helicobacter pylori Species 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 102100037907 High mobility group protein B1 Human genes 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 101001109463 Homo sapiens NACHT, LRR and PYD domains-containing protein 1 Proteins 0.000 description 1
• 101000979572 Homo sapiens NLR family CARD domain-containing protein 4 Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 229940122390 Inflammasome inhibitor Drugs 0.000 description 1
• 102100037850 Interferon gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 229940118432 Interleukin receptor antagonist Drugs 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
• 102100027670 Islet amyloid polypeptide Human genes 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 241000588748 Klebsiella Species 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 239000005639 Lauric acid Substances 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 241000222722 Leishmania <genus> Species 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 241000186779 Listeria monocytogenes Species 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical class [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 208000016285 Movement disease Diseases 0.000 description 1
• 101000933115 Mus musculus Caspase-4 Proteins 0.000 description 1
• 241000186362 Mycobacterium leprae Species 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 241000204048 Mycoplasma hominis Species 0.000 description 1
• 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
• 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 102100022698 NACHT, LRR and PYD domains-containing protein 1 Human genes 0.000 description 1
• 229910017906 NH3H2O Inorganic materials 0.000 description 1
• 102100023435 NLR family CARD domain-containing protein 4 Human genes 0.000 description 1
• 241000588650 Neisseria meningitidis Species 0.000 description 1
• 241000244206 Nematoda Species 0.000 description 1
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
• JRYJZQGKZUQYAL-QGZVFWFLSA-N O1CCC2(CC1)[C@@H](C1=CC=CC=C1C2)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2 Chemical compound O1CCC2(CC1)[C@@H](C1=CC=CC=C1C2)NC(=O)NS(=O)(=O)C=1C=NN2C=1OCCC2 JRYJZQGKZUQYAL-QGZVFWFLSA-N 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 235000021314 Palmitic acid Nutrition 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 241000282520 Papio Species 0.000 description 1
• NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 201000005702 Pertussis Diseases 0.000 description 1
• 241000224016 Plasmodium Species 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 102000005583 Pyrin Human genes 0.000 description 1
• 108010059278 Pyrin Proteins 0.000 description 1
• ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 235000004443 Ricinus communis Nutrition 0.000 description 1
• 241000606695 Rickettsia rickettsii Species 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 229910006074 SO2NH2 Inorganic materials 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 241000193996 Streptococcus pyogenes Species 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 102000000551 Syk Kinase Human genes 0.000 description 1
• 108010016672 Syk Kinase Proteins 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 229920002253 Tannate Polymers 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 206010067774 Tumour necrosis factor receptor-associated periodic syndrome Diseases 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 241000607479 Yersinia pestis Species 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
• SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 239000003655 absorption accelerator Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• QZWNXXINFABALM-UHFFFAOYSA-N adamantan-2-amine Chemical compound C1C(C2)CC3CC1C(N)C2C3 QZWNXXINFABALM-UHFFFAOYSA-N 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 239000001361 adipic acid Substances 0.000 description 1
• 235000011037 adipic acid Nutrition 0.000 description 1
• 229960000250 adipic acid Drugs 0.000 description 1
• 238000012387 aerosolization Methods 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 229960004909 aminosalicylic acid Drugs 0.000 description 1
• 229950003153 amsonate Drugs 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229960003121 arginine Drugs 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 229960005261 aspartic acid Drugs 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
• UGBKOURNNQREPE-UHFFFAOYSA-N azepan-1-amine Chemical compound NN1CCCCCC1 UGBKOURNNQREPE-UHFFFAOYSA-N 0.000 description 1
• 125000003725 azepanyl group Chemical group 0.000 description 1
• 201000008680 babesiosis Diseases 0.000 description 1
• 229940065181 bacillus anthracis Drugs 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 235000012216 bentonite Nutrition 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 235000012241 calcium silicate Nutrition 0.000 description 1
• LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000006721 cell death pathway Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 239000002458 cell surface marker Substances 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 238000005660 chlorination reaction Methods 0.000 description 1
• 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
• IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000002301 combined effect Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Chemical class 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
• 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
• HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
• YOXHCYXIAVIFCZ-UHFFFAOYSA-N cyclopropanol Chemical compound OC1CC1 YOXHCYXIAVIFCZ-UHFFFAOYSA-N 0.000 description 1
• WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
• 210000004292 cytoskeleton Anatomy 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 231100000895 deafness Toxicity 0.000 description 1
• 229960002887 deanol Drugs 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 150000001975 deuterium Chemical group 0.000 description 1
• 125000004431 deuterium atom Chemical group 0.000 description 1
• AZSZCFSOHXEJQE-UHFFFAOYSA-N dibromodifluoromethane Chemical compound FC(F)(Br)Br AZSZCFSOHXEJQE-UHFFFAOYSA-N 0.000 description 1
• ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• ROORDVPLFPIABK-UHFFFAOYSA-N diphenyl carbonate Chemical compound C=1C=CC=CC=1OC(=O)OC1=CC=CC=C1 ROORDVPLFPIABK-UHFFFAOYSA-N 0.000 description 1
• MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
• 239000001177 diphosphate Substances 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 208000016097 disease of metabolism Diseases 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 230000004771 dopaminergic neurodegeneration Effects 0.000 description 1
• 210000005064 dopaminergic neuron Anatomy 0.000 description 1
• 230000003291 dopaminomimetic effect Effects 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000003221 ear drop Substances 0.000 description 1
• 229940047652 ear drops Drugs 0.000 description 1
• 229940009662 edetate Drugs 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 150000002085 enols Chemical class 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 229950000206 estolate Drugs 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 125000005469 ethylenyl group Chemical group 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 230000004907 flux Effects 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000004077 genetic alteration Effects 0.000 description 1
• 231100000118 genetic alteration Toxicity 0.000 description 1
• 229960005219 gentisic acid Drugs 0.000 description 1
• 229960001731 gluceptate Drugs 0.000 description 1
• KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 229960002442 glucosamine Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 229940049906 glutamate Drugs 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 230000034659 glycolysis Effects 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 229940037467 helicobacter pylori Drugs 0.000 description 1
• 244000000013 helminth Species 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 230000009716 hepatic expression Effects 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• LBVQLNOQOXKBSE-UHFFFAOYSA-N heptane;propan-2-yl acetate Chemical compound CCCCCCC.CC(C)OC(C)=O LBVQLNOQOXKBSE-UHFFFAOYSA-N 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• 125000006038 hexenyl group Chemical group 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229960002885 histidine Drugs 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 230000024949 interleukin-17 production Effects 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 108091008582 intracellular receptors Proteins 0.000 description 1
• 102000027411 intracellular receptors Human genes 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 229940099584 lactobionate Drugs 0.000 description 1
• JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
• 229940099563 lactobionic acid Drugs 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 210000004558 lewy body Anatomy 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 208000018191 liver inflammation Diseases 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 229960003646 lysine Drugs 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 229940091250 magnesium supplement Drugs 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical class [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 210000003071 memory t lymphocyte Anatomy 0.000 description 1
• COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229940102396 methyl bromide Drugs 0.000 description 1
• LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000004065 mitochondrial dysfunction Effects 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 230000003959 neuroinflammation Effects 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 230000008779 noncanonical pathway Effects 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 229960002446 octanoic acid Drugs 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• 229960002969 oleic acid Drugs 0.000 description 1
• 239000008203 oral pharmaceutical composition Substances 0.000 description 1
• 239000000668 oral spray Substances 0.000 description 1
• 229940041678 oral spray Drugs 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 229960005010 orotic acid Drugs 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 229940116315 oxalic acid Drugs 0.000 description 1
• LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• 229940098695 palmitic acid Drugs 0.000 description 1
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 229940014662 pantothenate Drugs 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• 239000008249 pharmaceutical aerosol Substances 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• LPLJRIVBABWKHJ-UHFFFAOYSA-N phenyl N-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)carbamate Chemical compound N1=CC(=C2N1CCCO2)S(=O)(=O)NC(=O)OC1=CC=CC=C1 LPLJRIVBABWKHJ-UHFFFAOYSA-N 0.000 description 1
• BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 229920001515 polyalkylene glycol Polymers 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 229920000768 polyamine Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
• WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 230000001698 pyrogenic effect Effects 0.000 description 1
• 230000009873 pyroptotic effect Effects 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 230000000171 quenching effect Effects 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 201000002793 renal fibrosis Diseases 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• 229940075118 rickettsia rickettsii Drugs 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 229940116353 sebacic acid Drugs 0.000 description 1
• 239000008299 semisolid dosage form Substances 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 229910001494 silver tetrafluoroborate Inorganic materials 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 238000010922 spray-dried dispersion Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000003206 sterilizing agent Substances 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 238000006277 sulfonation reaction Methods 0.000 description 1
• 229940071103 sulfosalicylate Drugs 0.000 description 1
• XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
• BUXTXUBQAKIQKS-UHFFFAOYSA-N sulfuryl diisocyanate Chemical compound O=C=NS(=O)(=O)N=C=O BUXTXUBQAKIQKS-UHFFFAOYSA-N 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
• 229960004559 theobromine Drugs 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960004418 trolamine Drugs 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 229960002703 undecylenic acid Drugs 0.000 description 1
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
• 239000011787 zinc oxide Substances 0.000 description 1